Rigel Pharmaceuticals invites ASCO26 attendees to visit booth at major industry event

Rigel Pharmaceuticals invites ASCO26 attendees to visit booth at major industry event
Rigel Pharmaceuticals at ASCO Meeting

Rigel Pharmaceuticals announced its participation in the ASCO Annual Meeting, aiming to connect with oncology professionals and industry peers.

The company encouraged attendees to visit their booth, number 33080, to learn more about its latest developments and initiatives. The meeting provides an important platform for pharmaceutical companies to engage with stakeholders and showcase ongoing projects within the cancer research community.

Rigel recently signed a global license agreement to develop and commercialize VEPPANU (vepdegestrant). The company’s partner Kissei also filed a New Drug Application in Japan for olutasidenib to treat relapsed acute myeloid leukemia. These initiatives expand Rigel’s portfolio in oncology and related fields.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.